Skip to main content
Journal cover image

Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.

Publication ,  Journal Article
Payk, SL; Drew, RH; Smith, JD; Jiroutek, MR; Holland, MA
Published in: Clin Ther
July 1, 2015

PURPOSE: Although newer agents (dipeptidyl peptidase [DPP]-4 inhibitors and glucagon-like peptide [GLP]-1 receptor agonists) are available for the treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM), the impact of the availability of these agents on the use of second-generation sulfonylureas (SUs) is unknown. This article presents percentages of patients prescribed SUs, using data from the National Ambulatory Medical Care Survey (NAMCS). The associations between SU prescribing and prespecified variables of interest were also explored. METHODS: The NAMCS database was queried for visits of patients aged ≥18 years with an International Classification of Diseases, Ninth Revision diagnostic code relevant to T2DM. χ(2) tests were conducted to assess the associations between SU use and year-group (2003-2004, 2007-2008, or 2009-2010) and other variables of interest. A multivariate logistic regression model was constructed to jointly assess the value of these variables in predicting SU use. All analyses were weighted using procedures recommended by the National Center for Health Statistics. FINDINGS: Data from 7042 eligible visits were included, representing an extrapolated national estimate of 280,733,405 patient visits. The percentages of patients who received a prescription for an SU, by study year, were 25.7%, 23.4%, and 23.7% in 2003 to 2004, 2007 to 2008, and 2009 to 2010, respectively (P = 0.57). In the multivariate model, age ≥70 years, male sex, nonwhite race, primary care physician seen, and concurrent DPP-4 inhibitor use were significantly associated with SU use. IMPLICATIONS: No significant decrease in the use of SUs was observed after the introduction of DPP-4 inhibitors and GLP-1 receptor agonists. However, patient-specific factors (eg, select demographic variables, site of care, and concurrent medication use) were associated with SU use.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Ther

DOI

EISSN

1879-114X

Publication Date

July 1, 2015

Volume

37

Issue

7

Start / End Page

1477 / 1482.e1

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Sulfonylurea Compounds
  • Practice Patterns, Physicians'
  • Optoelectronics & Photonics
  • Middle Aged
  • Male
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Payk, S. L., Drew, R. H., Smith, J. D., Jiroutek, M. R., & Holland, M. A. (2015). Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. Clin Ther, 37(7), 1477-1482.e1. https://doi.org/10.1016/j.clinthera.2015.04.011
Payk, Stephanie L., Richard H. Drew, Jennifer D. Smith, Michael R. Jiroutek, and Melissa A. Holland. “Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.Clin Ther 37, no. 7 (July 1, 2015): 1477-1482.e1. https://doi.org/10.1016/j.clinthera.2015.04.011.
Payk SL, Drew RH, Smith JD, Jiroutek MR, Holland MA. Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. Clin Ther. 2015 Jul 1;37(7):1477-1482.e1.
Payk, Stephanie L., et al. “Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.Clin Ther, vol. 37, no. 7, July 2015, pp. 1477-1482.e1. Pubmed, doi:10.1016/j.clinthera.2015.04.011.
Payk SL, Drew RH, Smith JD, Jiroutek MR, Holland MA. Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. Clin Ther. 2015 Jul 1;37(7):1477-1482.e1.
Journal cover image

Published In

Clin Ther

DOI

EISSN

1879-114X

Publication Date

July 1, 2015

Volume

37

Issue

7

Start / End Page

1477 / 1482.e1

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Sulfonylurea Compounds
  • Practice Patterns, Physicians'
  • Optoelectronics & Photonics
  • Middle Aged
  • Male
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans